Skip to content

Faculty Member

Geoffrey Liu MD MSc

Email Address(es)
Office Phone
416-946-4501 x 3428
Office Address
Princess Margaret Hospital/Ontario Cancer Institute 610 University Avenue, 7-124 Toronto, ON M5G2M9
UHN Profile, COMBIEL: Cancer Outcomes Medicine Biostatistics Informatics Epidemiology Laboratory
Epidemiology Division
SGS Status
Full Member
Appointment Status
Non budgtry Crss

Research Interests

  • Pharmacogenetic Epidemiology of Cancer Outcomes
  • Radiogenomic Epidemiology of Cancer Outcomes
  • Cancer Survivorship
  • Molecular Epidemiology of Cancer
  • Methods Research in Biomarker and Correlative Science of Clinical Trials
  • Methods Research in Performing Large Scale Molecular Epidemiologic Studies of Outcome in Head and neck, Gastroesophageal, Lung, Hepatobiliary and pancreactic, and Testicular cancers, Thymomas and Mesotheliomas
  • Methods Research in Large Scale Collection of Cancer Patient Reported Outcomes Integration of outcomes and epidemiological research to improve pharmacogenetic
  • Knowledge Translation Research in Pharmacogenetics

Education & Training History

B.Sc. University of Toronto, Biochemistry/Human Biology

M.D. University of Toronto

M.Sc. University of Toronto, Clincial Epidemiology

Other Affiliations

  • Cancer Care Ontario (CCO) Research Chair in Experimental Therapeutics and Population Studies
  • American Board of Internal Medicine, Medical Oncology Board Certification
  • Canadian Society of Epidemiology and Biostatistics – Member
  • Pharmacogenetics Research Network – Affiliate Member
  • International Society for Pharmacoepidemiology (ISPE) – Member
  • National Lung Cancer Partnership (formerly Women Against Lung Cancer) – Lifetime Member
  • International Association for the Study of Lung Cancer – Member
  • Molecular Epidemiology Group, AACR – Member
  • American Association of Cancer Research (AACR) – Member
  • American Society of Clinical Oncology (ASCO) – Member

Primary Teaching Responsibilities

  • Pharmacogenetic Epidemiology
  • Supervision of students and post-doctoral fellows
  • COMBIEL training sessions: twice per week in the summer, and biweekly during the academic year, which involve a mix of didactic and problem-solving real case examples from the trainee projects

Professional Summary & Appointments

  • Associate Professor, Departments of Medicine, Medical Biophysics, and Epidemiology, University of Toronto, and Dalla Lana School of Public Health
  • Co-Director, COMBIEL, Cancer Outcomes, Medicine, Biostatistics, Informatics Epidemiology and Laboratory Interdisciplinary Training Initiative, Princess Margaret Hospital and Ontario Cancer Institute
  • Co-Director, On-PROST, Ontario Patient Reported Outcomes of Symptoms and Toxicity, Applied Clinical Research Unit
  • Cancer Care Ontario (CCO) Research Chair in Experimental Therapeutics and Population Studies, Ontario, Canada
  • Director, Applied Molecular Profiling Pharmacogenetic Epidemiology Laboratory (AMPPEL)
  • Alan B. Brown Chair in Molecular Genomics, Princess Margaret Hospital and Ontario Cancer Institute, University of Toronto, Toronto, ON
  • Staff Physician, University Health Network, Toronto, ON
  • Staff Physician, Mount Sinai Hospital, Toronto, ON

Honours & Awards

  • Alan B. Brown Chair in Molecular Genomics, Princess Margaret Hospital
  • Cancer Care Ontario Chair in Experimental Therapeutics and Population Studies
  • 2008 Chair, International Society of Pharmacoepidemiology, Molecular Epidemiology and Pharmacogenetics Working Group
  • 2008 William E. Rawls Award, National Cancer Institute of Canada
  • 2001-2007 Doris Duke Clinician Scienti

Current Research Projects

  • 1999 – current: Molecular and Pharmacogenetic Epidemiology of Esophageal Cancer Survival (funded by CIHR, NCI(US))
  • 2006 – current: Molecular and Pharmacogenetic Epidemiology of Lung Cancer Prognosis (funded by OICR, Lung Cancer Foundation of America)
  • 2007 – current: Genetic Polymorphisms and Head and Neck Cancer Survival (funded by CCSRI)
  • 2006 – current: Mesothelioma and serologic biomarkers
  • 2007 – current: Biomarkers in Early Detection of Lung Cancer Risk and Screening (funded by TRFI)
  • 2008 – current; In vivo Pharmacogenomics testing of primary human gastroesophageal cancer xenografts; development and characterization of new xenograft models
  • 2008 – current; Tumour initiating cells in gastroesophageal cancer
  • 2008 – current; BRM pathway, germline polymorphisms and lung cancer risk
  • 2009 – current: Methodological development of retrospective cancer data collection in Ontario (funded by CCO)
  • 2009 – current; Novel resistance mechanisms in testicular cancer therapy
  • 2011 – current; Pancreatic cancer pharmacogenetics (funded by OICR)
  • 2011 – current; On-PROST: Ontario patient reported outcomes of symptoms and toxicity (funded by CCO)
  • 2012 – current; Ovarian cancer pharmacogenetics (funded by CIHR)
  • 2012 – current; Resectable gastric cancer response to chemotherapy (funded by CIHR)

Representative Publications

Ten selected of over 100. Underlined names are supervised by G. Liu

1. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, Mackay HJ, Amir E, Liu G. p53 Arg72Pro Polymorphism, HPV status and Initiation, Progression and Development of Cervical Cancer: A Systematic Review and Meta-analysis. Clin Cancer Res. 2012 Oct 12. [Epub ahead of print]

2. Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, Savas S, Mackay HJ, Amir E, Liu G. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: A systematic review and meta-analysis. Clin Cancer Res. 2012 Sep 1;18(17):4526-37. Epub 2012 Jun 25

3. Azad AK, Bairati I, Samson E, Cheng D, Cheng L, Mirshams M, Savas S, Waldron J, Goldstein D, Xu W, Meyer F, Liu G. Genetic Sequence Variants and the Development of Secondary Primary Cancers in Patients with Head and Neck Cancers. Cancer. 2011 Aug 25. doi: 10.1002/cncr.26446.

4. Abul Kalam Azad, Elodie Samson, Dangxiao Cheng, Maryam Mirshams, Sevtap Savas, John Waldron, Wei Xu, Isabelle Bairati, Francois Meyer, Geoffrey Liu. Validation of Genetic Sequence Variants as Prognostic Factors in Early Stage Head and Neck Squamous Cell Cancer Survival. Clin Cancer Res. 2012 Jan 1;18(1):196-206. Epub 2011 Nov 10.

5. Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G. A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies. Cancer Epidemiol Biomarkers Prev., 2008; 17(1):204-11.

6. Bradbury PA, Kulke MH, Heist RS, Pintilie M, Zhou W, Marshall AL, Asomaning K, Su L, Nishioka NS, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G. DNA Repair Gene Polymorphisms Predict Clinical Outcome. Pharmacogenet Genomics. 2009 Aug;19(8):613-25.

7. Cheung WY, Zhai R, Kulke M, Heist RS, Asomaning K, Ma C, Wang Z, Su L, Lanuti M, Tanabe KK, Christiani DC, Liu G. Epidermal Growth Factor (EGF) A61G Gene Polymorphism, Gastroesophageal Reflux Disease (GERD), and Esophageal Adenocarcinoma (EAC) Risk. Carcinogenesis. 2009 Aug;30(8):1363-7.

8. Cescon DW, Bradbury PA, Asomaning K, Zhai R, Hopkins J, Kulke MH, Su L, Heist RS, Wain JC, Lynch TJ, Christisani DC, Liu G. p53, MDM2, and CCND1 polymorphisms in esophageal cancer prognosis. Clin Cancer Res. Clin Cancer Res. 2009 May 1;15(9):3103-9.

9. Savas S, Geraci J, Jurisica I, Liu G. A comprehensive catalogue of functional genetic variations from the EGFR pathway: protein-protein interaction analysis reveals novel genes and polymorphisms important for cancer research. Int J Cancer 2009 Sep 15;125(6):1257-65.

10. Wheatley-Price P, Yang B, Patel D, Ma C, Xu W, Anraku M, O’Sullivan B, Leighl N, Ron Feld, Cho BCJ, de Perrot M, Liu G. Mesothelin as a marker of response in malignant pleural mesothelioma. J Clin Oncol 2010 Jul 10;28(20):3316-22.